Alzamend Neuro Reports 61% Decrease in Quarterly Net Loss, Advances Clinical Pipeline

Alzamend Neuro, Inc. has reported significant financial developments in its latest 10-Q filing for the quarter ending January 31, 2025. The company, which focuses on developing treatments for Alzheimer’s disease and other neuropsychiatric disorders, recorded a net loss of $1.0 million for the quarter, a 61% decrease from the $2.7 million loss reported in the same period last year. For the nine months ending January 31, 2025, the net loss was $3.4 million, down from $9.1 million in the prior year, reflecting a 63% reduction in losses. The basic and diluted net loss per share improved to $(0.19) from $(3.77) year-over-year.

The company’s total operating expenses for the three months ended January 31, 2025, were $1.0 million, a significant decrease of 61% compared to $2.7 million in the same quarter of 2024. This reduction was primarily driven by a sharp decline in research and development expenses, which fell by 77% to $447,111 from $1.9 million, as the company scaled back on clinical trial activities. General and administrative expenses also decreased by 21% to $590,304, down from $751,173 in the previous year.

In terms of strategic developments, Alzamend has made notable progress in its clinical pipeline. The company is advancing two product candidates: AL001, a novel lithium formulation, and ALZN002, an immunotherapy vaccine for Alzheimer’s. The company has partnered with Massachusetts General Hospital to conduct five clinical trials for AL001, which aims to improve lithium delivery to the brain while minimizing side effects. Additionally, Alzamend has engaged in financing activities, raising approximately $9.0 million through the sale of Series A Convertible Preferred Stock and common stock, which has bolstered its cash position to $3.4 million as of January 31, 2025.

Operationally, Alzamend has not generated any revenue to date, as its products remain in the clinical development stage. The company reported a total of 6,597,507 shares of common stock outstanding as of March 7, 2025. The management has expressed concerns regarding its ability to continue as a going concern, citing the need for additional capital to fund ongoing operations and clinical trials. The company plans to finance its future activities primarily through equity sales and is actively seeking to raise further funds to support its development programs.

Looking ahead, Alzamend anticipates continued losses as it invests in the clinical development of its product candidates. The company is focused on advancing its research and development efforts while managing its cash flow to ensure operational sustainability. The management remains optimistic about the potential of its therapies and is committed to addressing the challenges of funding and regulatory approval in the biopharmaceutical landscape.